RxDoctor Payments DataLook up a doctor →

Ashley Vinson

Nurse Practitioner · Macon, GANPI 1437633229

Payments from drug & device makers

$10,817in general payments, 2019–2025

Across 378 payments — averaging $28.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$3K
  • Exelixis Inc.$2K
  • AstraZeneca$472
  • Merck$463
  • AbbVie$389
  • Pfizer$364
  • plus $5K from 54 others

What the payments were for

  • Food & beverage$8,33577%
  • Education$5025%
  • Other$1,97918%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis59$2,747
Exelixis Inc.11$1,546
AstraZeneca(2 entities)21$472
Merck25$463
AbbVie17$389
Pfizer20$364
Astellas Pharma US Inc11$360
Johnson & Johnson17$336
Seagen Inc.14$321
Pharmacyclics LLC, An Abbvie Company11$273
Genentech USA, Inc.13$250
Myriad Genetic Laboratories, Inc.4$230
Amgen9$222
Bristol Myers Squibb11$202
Regeneron Healthcare Solutions, Inc.7$150
Takeda Pharmaceuticals U.S.A., Inc.5$143
Stemline Therapeutics Inc.6$137
Daiichi Sankyo Inc.5$127
Eisai Inc.6$117
Beigene USA, Inc.6$104
AVEO Pharmaceuticals, Inc.4$103
Sanofi6$99
Blueprint Medicines Corporation5$97
Bayer5$95
Sobi, Inc4$88
Karyopharm Therapeutics Inc.5$85
GSK4$84
Lilly USA, LLC5$84
Boehringer Ingelheim3$78
Puma Biotechnology, Inc.4$76
Incyte Corporation5$74
E.r. Squibb & Sons, L.L.C.5$74
Gilead3$65
Mirati Therapeutics, Inc.4$64
Ipsen Biopharmaceuticals, Inc3$56
Servier Pharmaceuticals LLC3$46
Tersera Therapeutics LLC2$44
Deciphera Pharmaceuticals Inc.2$42
Rigel Pharmaceuticals, Inc.2$39
Genmab U.S., Inc.2$38
EMD Serono, Inc.2$37
Adaptive Biotechnologies Corporation2$35
Mindray DS USA, Inc.1$32
Coherus Oncology, Inc.2$30
ADC Therapeutics America, Inc.2$28
Medtronic1$26
Jazz Pharmaceuticals Inc.1$25
Acrotech Biopharma Inc.1$21
Taiho Oncology, Inc.1$21
Sun Pharmaceutical Industries Inc.1$20
Morphosys, US Inc.1$19
Dendreon Pharmaceuticals LLC1$19
G1 Therapeutics, Inc.1$18
Agios Pharmaceuticals, Inc.1$17
Shield Therapeutics Inc1$17
Pharmacosmos Therapeutics Inc.1$16
Pharmaessentia USA Corporation1$15
Array Biopharma Inc1$15
Dova Pharmaceuticals1$13
Global Blood Therapeutics, Inc.1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,817 in reported general payments places this provider in the 95th percentile of 3,328 nurse practitioner providers in Georgia.

See all nurse practitioner providers in Georgia

Medicare billing

Part B allowed, 2024
$24,343
Medicare patients
160
Services billed
351

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RevlimidLenalidomide22$366,234
Lenalidomide21$310,980
PomalystPomalidomide13$298,132
IbrancePalbociclib12$186,519
NubeqaDarolutamide14$182,568
XtandiEnzalutamide13$178,872
EliquisApixaban21$12,298
Ondansetron Hcl66$1,248
Anastrozole49$797
Dexamethasone50$527
Letrozole27$439
Lidocaine-PrilocaineLidocaine/Prilocaine33$427
Promethazine Hcl41$356
Olanzapine18$244
Prednisone29$189

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bristol Myers SquibbRevlimid$202$366,23422 claims
E.r. Squibb & Sons, L.L.C.Pomalyst$74$298,13213 claims
PfizerIbrance, Eliquis$364$198,81733 claims
BayerNubeqa$95$182,56814 claims
Astellas Pharma US IncXtandi$360$178,87213 claims
Lilly USA, LLCOlanzapine$84$24418 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,328 nurse practitioner providers in Georgia.

Other nurse practitioner in Macon

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →